Compare Citius Pharmaceuticals Inc (CTXR) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Northrop Grumman Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Northrop Grumman Corporation trades at $531.42 (market cap $75.09B). The key difference: Northrop Grumman Corporation is far larger — about 5129.1× Citius Pharmaceuticals Inc's market cap, and Northrop Grumman Corporation pays a 1.78% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NOC | |
|---|---|---|
Market Cap | $14.64M | $75.09B |
Sector | Health | Industrials |
52-Week High | $1.82 | $768.02 |
52-Week Low | $0.53 | $496.02 |
Enterprise Value | $10.86M | $89.31B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Northrop Grumman (NOC) trades at $541.82, up 0.41% with neutral technical signals. The company shows strong fundamentals with consistent earnings beats, a 10.8% net income margin, and a $96 billion backlog supporting growth. Recent news highlights expansion in defense and aerospace sectors, driven by increased government spending and new contracts.
Outlook is positive with a consensus price target of $655, indicating 21% upside. Risks include political budget shifts and execution challenges. Analyst sentiment is bullish (57% buy ratings), but investors should monitor Q2 2026 earnings due July 21 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
